Cutler Group LP Revance Therapeutics, Inc. Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$18.32 - $30.66 $87,203 - $145,941	4,760 New	4,760 $87,000
Q1 2022 Apr 14, 2022	BUY	$12.36 - $20.31 $93,985 - $154,437	7,604 Added 821.17%	8,530 $166,000
Q4 2021 Jan 18, 2022	BUY	$12.46 - $27.87 $11,537 - $25,807	926 New	926 $15,000
Q1 2020 May 07, 2020	SELL	$12.46 - $27.81 $16,198 - $36,153	-1,300 Closed	0 $0
Q4 2019 Feb 06, 2020	SELL	$11.66 - $20.15 $1,166 - $2,014	-100 Reduced 7.14%	1,300 $21,000
Q4 2018 Feb 05, 2019	SELL	$18.06 - $24.96 $9,030 - $12,480	-500 Reduced 26.32%	1,400 $28,000
Q3 2018 Nov 07, 2018	BUY	$23.55 - $30.1 $4,710 - $6,020	200 Added 11.76%	1,900 $47,000
Q2 2018 Aug 10, 2018	BUY	$27.45 - $33.35 $16,470 - $20,010	600 Added 54.55%	1,700 $46,000
Q1 2018 May 11, 2018	SELL	$29.15 - $37.4 $43,725 - $56,100	-1,500 Reduced 57.69%	1,100 $33,000
Q4 2017 Jan 17, 2018	BUY	$24.55 - $36.3 $49,100 - $72,600	2,000 Added 333.33%	2,600 $92,000
Q3 2017 Oct 17, 2017	BUY	$22.55 - $28.1 $13,530 - $16,860	600	600 $16,000

232

82.1M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.